TABLE 4.
Genotype distribution between axSpA patients and controls, for ACTN3 and VDR polymorphisms: rs1815739 (R577X); rs2228570 (FokI), rs731236 (TaqI), and rs7975232 (ApaI).
| Genotype | Cases n (%) | Controls n (%) | p-value* | ORa (95% CI) |
| ACTN3 R577X | ||||
| C/C | 8 (30.8) | 6 (25.0) | 1.000 (reference) | |
| C/T | 15 (57.7) | 12 (50.0) | 0.463 | 0.375 (0.066–2.145) |
| T/T | 3 (11.5) | 6 (25.0) | 0.938 (0.255–3.449) | |
| C/T + T/T | 18 (69.2) | 18 (75.0) | 0.750 (0.216–2.602) | |
| VDR—FokI | ||||
| A/A | 4 (15.4) | 2 (8.3) | 1.000 (reference) | |
| A/G | 12 (46.2) | 16 (66.7) | 0.339 | 0.375 (0.059–2.397) |
| G/G | 10 (38.5) | 6 (25.0) | 0.833 (0.115–6.013) | |
| A/G + G/G | 22 (84.6) | 22 (91.7) | 0.500 (0.083–3.017) | |
| VDR—TaqI | ||||
| A/A | 11 (42.3) | 7 (30.4) | 1.000 (reference) | |
| A/G | 7 (26.9) | 9 (39.1) | 0.599 | 0.495 (0.126–1.945) |
| G/G | 8 (30.8) | 7 (30.4) | 0.727 (0.181–2.914) | |
| A/G + G/G | 15 (57.7) | 16 (69.6) | 0.597 (0.183–1.943) | |
| VDR—ApaI | ||||
| C/C | 7 (28.0) | 3 (12.5) | 1.000 (reference) | |
| C/A | 9 (36.0) | 10 (41.7) | 0.400 | 0.351 (0.070–1.761) |
| A/A | 9 (36.0) | 11 (45.8) | 0.386 (0.076–1.959) | |
| C/A + A/A | 18 (72.0) | 21 (87.5) | 0.367 (0.083–1.633) |
*p-value χ2-test. Abbreviations: a ORs and 95% CI for specific categories were calculated using logistic regression models; OR, odds ratio; CI, confidence interval.